ELEANOR: observing real-life extended adjuvant therapy with neratinib and concurrent use of CONKADO
Nadia Harbeck • 4 May 2022
Should polygenic risk scores be used to risk-stratify the use of PSA-screening in prostate cancer?
Andrew Vickers • 11 May 2022
Investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in HER2+ eBC
Benedetta Conte • 5 May 2022